Table 1.

Baseline disease characteristics (Calabresi et al. [5])

Characteristic	Placebo	Peginterferon beta-1a
		Every 4 weeks	Every 2 weeks
All patients, n	500	500	512
Relapses in the 12 months prior to enrolment, mean (SD)	1.6 (0.67)	1.5 (0.62)	1.6 (0.67)
Baseline EDSS score, mean (SD)	2.44 (1.18)	2.48 (1.24)	2.47 (1.26)
T2 lesions at baseline
Patients with available data, n	497	499	511
Mean number of lesions (SD)	50.6 (35.7)	51.4 (36.0)	48.7 (36.8)
Patients with no T2 lesions at baseline, n (%)	0	3 (<1)	4 (<1)
Gd + lesions at baseline
Patients with available data, n	497	498	510
Mean number of lesions (SD)	1.6 (3.8)	1.8 (5.4)	1.2 (3.4)
Patients with no Gd + lesions at baseline, n (%)	296 (59.6)	297 (59.6)	334 (65.5)

EDSS expanded disability status scale, Gd+ gadolinium-enhancing lesions, SD standard deviation